Share This

Create Your Own Business Intelligence Website   Input the stock code or the company name     Search   <02196.HK> - SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.    Stock Screener：Medicine, Pharmaceuticals HUTCHMED C.P. POKPHAND PAK FAH YEOW ALI HEALTH SIPAI HEALTH OCI INTL INNOVATIVE PHAR WANJIA GROUP TIANDA PHARMA SIHUAN PHARM LANSEN PHARMA GRAND PHARMA TRAD CHI MED PASHUN INT'L REGENT PACIFIC CONCH ENVIRO UNI-BIO GROUP SHANDONG XINHUA CKLIFE SCIENCES EXTRAWELL PHAR CMS BAIYUNSHAN PH WAI YUEN TONG ZHONG JIA GX QIANHAI HEALTH SHUNTEN INTL C ANIMAL HEALTH LEE'S PHARM NT PHARMA ESSEX BIO-TECH CSPC PHARMA SINOPHARM KINGWORLD CMBC CAPITAL CGN MINING SINO BIOPHARM KONTA CHINA SH PIONEER HLDG OCUMENSION-B PURAPHARM LIVZON PHARMA FRONTAGE 3SBIO HEC CJ PHARM MODERN CHI MED FUSEN PHARM TONG REN TANG CONSUN PHARMA CIRC SANAI HEALTH GP SSY GROUP SIMCERE PHARMA JBM HEALTHCARE LUYE PHARMA UNI HEALTH CHARMACY PHAR BIOCYTOGEN-B DAWNRAYS PHARMA WUXI APPTEC HUA MEDICINE-B SH PHARMA JACOBSON PHARMA SHINEWAY PHARM LONGRUN TEA CHINARES PHARMA SINOLIFE UTD TYCOON GROUP TONGRENTANGCM HANSOH PHARMA ZHONGZHIPHARM PHARMARON UNITED LAB NEW RAY MEDIC JOINN JD HEALTH ZHAOKE OPHTH-B AIM VACCINE ASYMCHEM SINCO PHARMA HINSANG GROUP GOLDEN THROAT HAO WEN HLDGS CB GLOBAL CH BIOTECH SER JILIN CHANGLONG CH DEMETER FIN GF HEALTHCARE CRMI BAYTACARE PHARM C HEALTH GP SILK RD ENERGY NEP INTERLONG LARRY JEWELRY    Basic Datum Company name Lot P/E P/B EPS DPS FOSUN PHARMA 500 17.23 0.6313 0.9866 0.296 Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend    Related links    Related news    復星醫藥控股子公司藥物註冊申請獲國家藥監局受理   復星醫藥子公司藥物獲批開展臨床試驗   復星醫藥子公司兩款藥物註冊申請獲國家藥監局受理   復星醫藥與深圳引導基金成立合資基金   《公司業績》復星醫藥全年純利23.99億人幣跌35.8% 派...   復星醫藥子公司復星雅立峰通過GMP符合性檢查  ≫More    Company Rating Date Broker Company name Rating Target 02-21  HSBC   FOSUN PHARMA  持有 25 11-01  G.Sachs   FOSUN PHARMA  中性 12.6 ≫More    Company performance - Published Date Company name Turnover* Profit* % Dividend ≫More    Comment 2022-04-27　復星醫藥（2196）今年首季純利按年大幅下跌45.4%，至4.62億元人民幣，季內表現主要受累於旗下投資BioNTech（美：BNTX）等金融資產的股價下跌。   2022-04-27　截至今年3月底，復必泰在港澳台累計接種逾2400萬劑疫苗。據報道，中國擬考慮引入復必泰疫苗，復星醫藥昨日股價升逾7%，收報34.55港元。   2022-04-27　復星醫藥首季收益主要受惠於mRNA新冠疫苗復必泰、注射用曲妥珠單抗「漢曲優」、馬來酸阿伐曲泊帕片「蘇可欣」、肝素系列製劑等產品的增長貢獻。   2022-04-27　復星醫藥上季已獲許可，向中低收入的國家供應默沙東研發的新冠藥物Molnupiravir、輝瑞新冠藥物Nirmatrelvir等。旗下在上海建設的移動式方艙實驗室，也在今年3月正式啟動檢測。   2022-04-27　復星醫藥自研的新冠病毒抗原檢測試劑在本月初於中國境內獲批上市。此前，該產品已通過歐盟CE認證、完成德國BfArM註冊，獲列入歐盟衛生安全委員會HSC Common List（歐盟通用白名單）。      Top Gain / Loss Show All Charts     Value Name Updated Value Change Change % HSI 04-22 09:30 16513.6 ▲ 289.41 ▲ 1.78% FOSUN PHARMA 04-23 16:09 11.76 ▲ 11.76 ▲ ∞% ≫More

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.